Purpose Since atrial fibrillation (AF) is one of the major arrhythmias managed in hospitals
worldwide, it has a major impact on public health. The guidelines agree on the desirability of …

Purpose We sought to indirectly compare and rank antiarrhythmic agents focusing
exclusively on adults with paroxysmal atrial fibrillation in order to identify the most effective …

Aims Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical
practice. Episodes may stop spontaneously (paroxysmal AF); may terminate only via …

Purpose The available evidence to determine which antidysrhythmic drug is superior for
pharmacologic cardioversion of recent-onset (onset within 48 h) atrial fibrillation (AF) is …

Antiarrhythmic drugs remain the mainstay therapy for patients with atrial fibrillation (AF). A
major disadvantage of the currently available anti-AF agents is the risk of induction of …

Cardioversion (CV) is an essential component of rhythm control strategy in the treatment of
atrial fibrillation (AF). Timing of CV is an important manageable factor in optimizing the safety …

Background: Intravenous (IV) flecainide is recommended for the pharmacological
cardioversion of recent-onset atrial fibrillation (AF). The aim of this study was to study the …

Background Whether early pharmacologic cardioversion is necessary for recent-onset atrial
fibrillation is still controversial. Current meta-analyses were limited to evaluating the effects …

Background: The high recurrence rate of atrial fibrillation (AF) after recovering sinus rhythm
has always been a clinical problem. Despite the established and widespread use of …

Introduction Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical
practice and rhythm control using pharmacological agents is required in selected patients …